Stability has become a priority in GBCA choice, shifting attention towards macrocyclic agents^{1, 2}.

Macrocyclic, ionic GBCA:

Cage-like structure encloses and tightly binds the Gd³⁺ ion¹
Highly stable¹
Biologically inert¹
Rapid biodistribution and elimination³

Adding Inclusivity

Providing flexibility for everyday practice, with multiple indications across a breadth of patient types.

Clariscan is indicated for diagnostic contrast enhancement in³:

Whole body MRI including the major organs, pelvis, breast and muscoskeletal system (not recommended for children below 6 months)
MRI of the CNS including the brain, spine and surrounding tissue
MR angiography including lesions or stenoses of the non-coronary arteries

GBCA: gadolinium based contrast agents
MRI: magnetic resonance imaging
MR: magnetic resonance
CNS: central nervous system

Reference:
1. Tweedle MF et al. Considerations in the Selection of a New Gadolinium-Based Contrast Agent. Supplement to Applied Radiology. May 2014.
2. Weinreb JC. New Guidelines Use of Gadolinium Contrast Agents. Presented for the Society of Computed Body Tomography and Magnetic Resonance, June 2006.
3. Clariscan Summary of Product Characteristics (UK), April 2018.

Clariscan

Clariscan (gadoteric acid)

Expanding our portfolio, to offer you a macrocyclic agent expertly manufactured by GE Healthcare.

Adding confidence

Adding value

Adding possibilities